Systems Biology Analysis of the Antagonizing Effects of HIV-1 Tat Expression in the Brain over Transcriptional Changes Caused by Methamphetamine Sensitization.
Animals
Binding Sites
Brain
/ metabolism
Gene Expression Profiling
Gene Expression Regulation
/ drug effects
HIV Infections
/ virology
HIV-1
/ drug effects
Humans
Male
Methamphetamine
/ pharmacology
Mice
Mice, Transgenic
Mitochondria
/ metabolism
Protein Binding
Systems Biology
/ methods
Transcription Factors
/ metabolism
tat Gene Products, Human Immunodeficiency Virus
/ genetics
methamphetamine
transcriptome
transgenic Tat mouse
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
09 04 2020
09 04 2020
Historique:
received:
02
03
2020
revised:
27
03
2020
accepted:
01
04
2020
entrez:
15
4
2020
pubmed:
15
4
2020
medline:
23
2
2021
Statut:
epublish
Résumé
Methamphetamine (Meth) abuse is common among humans with immunodeficiency virus (HIV). The HIV-1 regulatory protein, trans-activator of transcription (Tat), has been described to induce changes in brain gene transcription that can result in impaired reward circuitry, as well as in inflammatory processes. In transgenic mice with doxycycline-induced Tat protein expression in the brain, i.e., a mouse model of neuroHIV, we tested global gene expression patterns induced by Meth sensitization. Meth-induced locomotor sensitization included repeated daily Meth or saline injections for seven days and Meth challenge after a seven-day abstinence period. Brain samples were collected 30 min after the Meth challenge. We investigated global gene expression changes in the caudate putamen, an area with relevance in behavior and HIV pathogenesis, and performed pathway and transcriptional factor usage predictions using systems biology strategies. We found that Tat expression alone had a very limited impact in gene transcription after the Meth challenge. In contrast, Meth-induced sensitization in the absence of Tat induced a global suppression of gene transcription. Interestingly, the interaction between Tat and Meth broadly prevented the Meth-induced global transcriptional suppression, by maintaining regulation pathways, and resulting in gene expression profiles that were more similar to the controls. Pathways associated with mitochondrial health, initiation of transcription and translation, as well as with epigenetic control, were heavily affected by Meth, and by its interaction with Tat in anti-directional ways. A series of systems strategies have predicted several components impacted by these interactions, including mitochondrial pathways, mTOR/RICTOR, AP-1 transcription factor, and eukaryotic initiation factors involved in transcription and translation. In spite of the antagonizing effects of Tat, a few genes identified in relevant gene networks remained downregulated, such as sirtuin 1, and the amyloid precursor protein (APP). In conclusion, Tat expression in the brain had a low acute transcriptional impact but strongly interacted with Meth sensitization, to modify effects in the global transcriptome.
Identifiants
pubmed: 32283831
pii: v12040426
doi: 10.3390/v12040426
pmc: PMC7232389
pii:
doi:
Substances chimiques
Transcription Factors
0
tat Gene Products, Human Immunodeficiency Virus
0
Methamphetamine
44RAL3456C
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDA NIH HHS
ID : P50 DA026306
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA036164
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA047822
Pays : United States
Références
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3760-5
pubmed: 15728729
J Biol Chem. 2003 Apr 11;278(15):13512-9
pubmed: 12551932
J Neurovirol. 2018 Apr;24(2):156-167
pubmed: 29075998
Mol Cell Neurosci. 2004 Nov;27(3):296-305
pubmed: 15519244
Eval Health Prof. 2018 Dec;41(4):474-492
pubmed: 28835116
Infect Disord Drug Targets. 2012 Feb;12(1):81-6
pubmed: 22280310
J Immunol. 2001 Nov 1;167(9):5429-38
pubmed: 11673562
FASEB J. 2013 Sep;27(9):3720-9
pubmed: 23752207
J Neurovirol. 2000 Apr;6(2):145-55
pubmed: 10822328
Drug Alcohol Depend. 2011 Jan 1;113(1):1-7
pubmed: 20705401
Elife. 2015 Oct 21;4:
pubmed: 26488441
J Neurovirol. 2011 Feb;17(1):3-16
pubmed: 21174240
Mol Cell Neurosci. 2003 Sep;24(1):224-37
pubmed: 14550782
Pharmacol Ther. 2003 Jul;99(1):45-53
pubmed: 12804698
Neurobiol Aging. 2008 Aug;29(8):1160-6
pubmed: 17420072
J Mol Diagn. 2003 May;5(2):73-81
pubmed: 12707371
Exp Neurol. 2015 Jan;263:221-34
pubmed: 25246228
Neurology. 2006 Mar 28;66(6):862-6
pubmed: 16567703
Nat Neurosci. 2019 Jul;22(7):1066-1074
pubmed: 31209380
Hum Genet. 2014 May;133(5):575-86
pubmed: 24253422
Neurotox Res. 2012 Jan;21(1):79-89
pubmed: 21948112
J Neurovirol. 2018 Apr;24(2):168-179
pubmed: 29143286
Cell Biol Int. 2010 Mar 12;34(4):409-13
pubmed: 19995346
AIDS. 1995 Apr;9(4):313-24
pubmed: 7794536
Appl Bioinformatics. 2003;2(4):209-17
pubmed: 15130792
J Neuroimmune Pharmacol. 2018 Jun;13(2):163-178
pubmed: 29280055
Behav Brain Res. 2012 Apr 1;229(1):48-56
pubmed: 22197678
J Neurosci. 2015 Jun 10;35(23):8843-54
pubmed: 26063917
J Neuroimmune Pharmacol. 2010 Mar;5(1):44-62
pubmed: 19697136
PLoS Comput Biol. 2014 Jul 24;10(7):e1003731
pubmed: 25058159
Am J Pathol. 2003 May;162(5):1693-707
pubmed: 12707054
Exp Gerontol. 2015 Aug;68:66-70
pubmed: 25449851
Pharmacol Biochem Behav. 1981 Dec;15(6):925-32
pubmed: 7323118
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13588-93
pubmed: 23898208
Brain Behav Immun. 2017 Oct;65:210-221
pubmed: 28495611
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D535-9
pubmed: 16381927
Synapse. 2009 Mar;63(3):181-5
pubmed: 19086089
PLoS One. 2017 Apr 26;12(4):e0175316
pubmed: 28445538
Addict Biol. 2014 Jul;19(4):593-605
pubmed: 23252824
Nature. 1994 Jan 13;367(6459):188-93
pubmed: 8114918
Epilepsia. 2015 May;56(5):e53-7
pubmed: 25847220
Rev Neurol. 2011 Jan 16;52(2):101-11
pubmed: 21271550
Neuropsychopharmacology. 2010 Jan;35(1):217-38
pubmed: 19710631
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:331-339
pubmed: 29574227
J Neuroimmunol. 2010 Jan 25;218(1-2):94-101
pubmed: 19913921
Synapse. 2012 Aug;66(8):755-7
pubmed: 22517264
J Neuroimmune Pharmacol. 2012 Sep;7(3):629-39
pubmed: 22570010
J Neuroimmune Pharmacol. 2016 Sep;11(3):495-510
pubmed: 27484318
Contrib Nephrol. 1994;107:194-204
pubmed: 8004968
AIDS Patient Care STDS. 2012 Jan;26(1):36-52
pubmed: 22070609
Mol Neurobiol. 2011 Aug;44(1):102-10
pubmed: 21717292
Eur J Haematol. 2009 Sep;83(3):235-45
pubmed: 19341427
J Neurochem. 2003 Jan;84(1):169-79
pubmed: 12485413
Psychoneuroendocrinology. 2008 Jul;33(6):755-65
pubmed: 18407425
Nat Struct Mol Biol. 2017 Apr;24(4):379-386
pubmed: 28218748
Nucleic Acids Res. 2001 Jan 1;29(1):281-3
pubmed: 11125113
J Virol. 1990 Oct;64(10):5226-9
pubmed: 2398545
Psychopharmacology (Berl). 2014 Jun;231(11):2349-60
pubmed: 24352568
BMC Res Notes. 2018 May 4;11(1):275
pubmed: 29728138
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Toxicol Lett. 2018 Dec 15;299:159-171
pubmed: 30261225
Front Immunol. 2019 Feb 04;9:3110
pubmed: 30778358
J Neuroinflammation. 2010 Nov 22;7:82
pubmed: 21092194
Neurosci Lett. 2014 Feb 7;560:103-6
pubmed: 24361545
Oncotarget. 2016 Jul 19;7(29):46100-46119
pubmed: 27323860
Neurobiol Dis. 2017 Sep;105:51-73
pubmed: 28457951
Curr Top Microbiol Immunol. 1996;206:223-41
pubmed: 8608719
Front Neurosci. 2018 Dec 06;12:921
pubmed: 30574066
Nihon Shinkei Seishin Yakurigaku Zasshi. 2008 Apr;28(2):85-91
pubmed: 18516987
Bioinformatics. 2005 Aug 15;21(16):3448-9
pubmed: 15972284
Mol Cell Oncol. 2014 Dec 03;2(2):e970489
pubmed: 27308421
Leukemia. 1999 Apr;13 Suppl 1:S78-80
pubmed: 10232371
Front Microbiol. 2015 Oct 23;6:1164
pubmed: 26557111
Neurology. 2015 Apr 14;84(15):1520-8
pubmed: 25770198
J Biol Chem. 1989 Dec 15;264(35):20823-6
pubmed: 2687263
J Neurovirol. 2019 Oct;25(5):648-660
pubmed: 31016584
Temperature (Austin). 2014 Oct-Dec;1(3):227-241
pubmed: 26346736
PLoS One. 2014 Jul 23;9(7):e102555
pubmed: 25054922
Neurol Sci. 2006 Sep;27(4):271-7
pubmed: 16998732
Neurosci Biobehav Rev. 2008 Jul;32(5):883-909
pubmed: 18430470
Mol Biol (Mosk). 1997 Jul-Aug;31(4):733-40
pubmed: 9340499
Oxid Med Cell Longev. 2018 Oct 29;2018:6124745
pubmed: 30647813
Neuroscience. 2003;117(1):43-53
pubmed: 12605891
J Pharmacol Exp Ther. 2009 Jun;329(3):1071-83
pubmed: 19325033
Neuropharmacology. 2016 Oct;109:205-215
pubmed: 27316905
Cell. 1996 Aug 23;86(4):517-20
pubmed: 8752206
Drug Alcohol Depend. 2008 Jul 1;96(1-2):90-8
pubmed: 18384978
Int J Neuropsychopharmacol. 2017 May 1;20(5):410-421
pubmed: 28034961
J Neurovirol. 2013 Feb;19(1):82-8
pubmed: 23329164
Brain. 2004 Nov;127(Pt 11):2452-8
pubmed: 15319273
Mol Cell Biol. 2018 May 29;38(12):
pubmed: 29610153
J Proteome Res. 2010 Apr 5;9(4):1795-804
pubmed: 20121167
J Neurochem. 2005 Oct;95(2):429-36
pubmed: 16086684
Brain Behav Immun. 2010 Mar;24(3):502-11
pubmed: 20035859
Neurobiol Aging. 2012 Aug;33(8):1579-90
pubmed: 21764480
J Psychoactive Drugs. 2003 May;35 Suppl 1:161-8
pubmed: 12825759
PLoS One. 2010 Jul 29;5(7):e11875
pubmed: 20686703
Eur J Hum Genet. 2001 Jun;9(6):469-72
pubmed: 11436130
J Neuroimmune Pharmacol. 2012 Dec;7(4):914-26
pubmed: 23065460
Mol Neurodegener. 2014 Jul 01;9:26
pubmed: 24980976
Curr HIV Res. 2019;17(2):126-133
pubmed: 31269883
PLoS Pathog. 2011 Sep;7(9):e1002213
pubmed: 21909266
Genome Biol. 2008;9 Suppl 1:S4
pubmed: 18613948
J Immunol. 2007 May 1;178(9):5812-9
pubmed: 17442965
Front Pharmacol. 2017 Sep 14;8:639
pubmed: 28959203
Front Endocrinol (Lausanne). 2013 Apr 23;4:44
pubmed: 23630518
Front Genet. 2018 Nov 23;9:561
pubmed: 30532767
Am J Psychiatry. 2005 Aug;162(8):1461-72
pubmed: 16055767
J Pharmacol Exp Ther. 2002 Feb;300(2):621-8
pubmed: 11805225
Neurosci Res. 2010 Jul;67(3):250-5
pubmed: 20394784